ArticleCureus2025
Effects of Stevia on Inflammatory Markers, Renal and Hematological Parameters in Patients With Stage I-III Chronic Kidney Disease: A Randomized, Placebo-Controlled Clinical Trial in Bangladesh.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Global public health policy is concerned about the increasing prevalence of chronic kidney disease (CKD) and its associated comorbidities. Stevioside has been confirmed by food regulatory and safety bodies to be safe and effective for treating diabetes and hypertension. Stevia has also demonstrated a nephroprotective effect in experimental animals. This clinical trial aimed to investigate the kidney-protective effects of stevioside in CKD Stage I-III patients, and to explore its impact on inflammatory markers, kidney function, and hematological parameters as a potential new treatment option. Methods The trial was a prospective, single-blind, placebo-controlled study with 93 participants (83 CKD patients at Stage I-III and 10 healthy controls). The 83 CKD patients were randomly assigned to stevia (250 mg twice daily) or placebo (in addition to standard care), and 10 healthy individuals served as a control group. The study was conducted at the Kidney Foundation Hospital and Research Institute, Dhaka, Bangladesh, from December 2016 to December 2018. Patients were scheduled for follow-up visits every three months for a total of nine months. Data were collected using a systematic, validated, and structured questionnaire. Results At baseline, 44.2% of the CKD patients were in Stage III; by the second follow-up, this proportion had dropped to 38.2%. Stevia treatment significantly reduced systolic blood pressure (p < 0.043), diastolic blood pressure (p < 0.001), microalbuminuria (p < 0.003), postprandial blood sugar (p < 0.001), erythrocyte sedimentation rate (p < 0.023), and high-sensitivity C-reactive protein (p < 0.007) levels at the second follow-up. During the washout period (with no stevia), most of these improved values trended back toward baseline in the stevia group, indicating a loss of the treatment effect upon withdrawal. Conclusion This nine-month clinical investigation found that oral stevia can positively impact biochemical indicators in CKD patients, potentially mitigating the progression of the disease. Therefore, stevia's benefits might offer new interventions to alleviate cardiovascular and metabolic risks in early-stage CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.